|By Marketwired .||
|July 25, 2014 08:00 AM EDT||
TOKYO, JAPAN -- (Marketwired) -- 07/25/14 -- REGiMMUNE Corporation, a biotechnology company focused on the development of immune regulatory therapeutics with its reVax technology, announced that it will present results from its research on its novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants at the World Transplant Congress (WTC) on Tuesday, July 29. The poster, "A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade," will be presented by Toshihito Hirai, MD, Department of Urology, Tokyo Women's Medical University, Tokyo. The WTC acknowledged the importance of REGiMMUNE's research by designating it as one of the top 100 papers submitted (or top 3%) for presentation at this international meeting.
Robust, lifelong, donor-specific tolerance can be reliably achieved by induction of mixed chimerism in various animal models of bone transplantation. To date, the clinical application of these protocols has been impeded by the potential toxicity of the required host conditioning regimens. The REGiMMUNE poster presents the potential of a novel approach using a ligand alpha-GalCer (aGC) for iNKT cells and suboptimal dosage of antibody that blocks CD40:CD40L signaling as a powerful method to generate mixed chimerism. The data suggest a new insight -- that the immune direction of iNKT cells is controlled through a type of APC presenting a-GalCer and costimulation signals, and that it is possible to enhance the innate ability of immune tolerance by appropriate activation of iNKT cells.
REGiMMUNE chief executive officer Yasuyuki Ishii, PhD, commented, "As described in our poster presentation, this combination therapy of aGC liposome with CD40/40L blockade offers great promise and another approach to induce solid organ transplant tolerance -- without continuous administration of immune suppressants -- that may be long lasting."
Abstract: "A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Co-stimulatory Blockade"
Invariant natural killer T (iNKT) cells are one of the innate lymphocytes that regulate immunity, although it is still elusive how iNKT cells should be manipulated for transplant tolerance. We previously reported that the liposomal formulation of a-galactosylceramide (Lipo-aGC ) could enhance immune-regulative aspect of iNKT cells compared to the conventional aGC. Here we describe a novel approach to induce mixed chimerism (MC ) by activating iNKT cells with Lipo-aGC under CD40-CD40L blockade (MR1). 3Gy irradiated BALB/c mice were transplanted with B6 bone marrow cells (BMC s) with/without Lipo-aGC and/or several dosages of MR1. Only combination therapy of Lipo-aGC plus suboptimal-MR1 showed robust MC. Mice established MC completely accepted subsequent cardiac allografts in a donor-specific manner. High amounts of Th2-cytokines were detected right after iNKT-cell activation, while subsequent IFN-γ production by NK cells was effectively inhibited by MR1. Expansion of regulatory T cells (Tregs) was observed in MC mice and Treg-depletion on 1 day before transplantation resulted MC brake. Further, iNKT-cell knockout mice failed both MC establishment and Tregs expansion. These results collectively suggest that our new protocol makes it possible to induce donor-specific tolerance by enhancement of the innate regulatory mechanism in place of the conventional immunosuppression.
Oral Abstract Session: "Tolerance/Immune Deviation"
Date: Tuesday, 7-29-2014
Time: 11:15 am - 12:45 pm
Publication Number: 1415
Presentation Time: 11:51 am
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company's proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan. REGiMMUNE is headquartered in Tokyo, Japan and has a US operation in San Francisco, California. For more information, visit www.regimmune.com.
Oct. 28, 2016 11:45 AM EDT Reads: 16,665
Oct. 28, 2016 11:30 AM EDT Reads: 2,100
Oct. 28, 2016 11:30 AM EDT Reads: 155
Oct. 28, 2016 11:00 AM EDT Reads: 2,272
Oct. 28, 2016 11:00 AM EDT Reads: 358
Oct. 28, 2016 10:32 AM EDT Reads: 212
Oct. 28, 2016 10:30 AM EDT Reads: 2,954
Oct. 28, 2016 09:15 AM EDT Reads: 11,629
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
Oct. 28, 2016 09:00 AM EDT Reads: 2,032
Enterprises have been using both Big Data and virtualization for years. Until recently, however, most enterprises have not combined the two. Big Data's demands for higher levels of performance, the ability to control quality-of-service (QoS), and the ability to adhere to SLAs have kept it on bare metal, apart from the modern data center cloud. With recent technology innovations, we've seen the advantages of bare metal erode to such a degree that the enhanced flexibility and reduced costs that cl...
Oct. 28, 2016 08:30 AM EDT Reads: 718
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Oct. 28, 2016 08:00 AM EDT Reads: 5,095
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 28, 2016 08:00 AM EDT Reads: 1,075
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 28, 2016 08:00 AM EDT Reads: 1,648
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
Oct. 28, 2016 08:00 AM EDT Reads: 3,531
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
Oct. 28, 2016 07:15 AM EDT Reads: 1,120